Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker

Urology

Volumn 49, Issue 6, 1997, Pages 857-862

  Darson, Micheal F ^a   Pacelli, Anna ^a   Roche, Patrick ^a   Rittenhouse, Harry G ^a   Wolfert, Robert L ^a   Young, Charles Y F ^a   Klee, George G ^a   Tindall, Donald J ^a   Bostwick, David G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER STAGING; DIAGNOSTIC VALUE; GENE EXPRESSION; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE TUMOR; PROSTATECTOMY;

ACID PHOSPHATASE; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030926344     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00108-8     Document Type: Article

References (21)

1. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 45:1995;729-744.
2. Ruckle HC, Klee GG, Oesterling JE. Prostate-specific antigen: critical issues for the practicing physician. Mayo Clin Proc. 69:1994;59-68.
3. Wang TJ, Hill TM, Sokoloff RL, Frankenne F, Rittenhouse HG, Wolfert RL. Dual monoclonal antibody immunoassay for free prostate-specific antigen. Prostate. 28:1996;10-16.
4. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadier RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
5. Rittenhouse HG, Tindall D, Klee GG, Young CY-F, Bostwick D, Saedi MM, Grauer L, Mikolajczyk S, Finlay J, Kuus-Reichel K, et al. Characterization and evaluation of hK2: a potential prostate cancer marker, closely related to PSA. Murphy GP, Khoury S. Proceedings of the First International Consultation on Prostate Cancer, June 1996, Monaco. 1997;Scientific Communication International Ltd, Jersey, Channel Islands. (in press).
6. Charlesworth MC, Young CY-F, Klee GG, Saedi MS, Mikolajczyk SD, Finlay JA, Tindall DJ. Detection of a prostate-specific protein, human glandular kallikrein 2 (hK2), in sera of patients with elevated prostate specific antigen levels. Urology. 1997;. (in press).
7. Lilja H. Structure, function and regulation of the enzyme activity of prostate-specific antigen. World J Urol. 11:1993;188-191.
8. Young CY-F, Andrews PE, Montgomery BT, Tindall DJ. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry. 31:1992;818-824.
9. Chapdelaine P, Paradis G, Tremblay RR, Dube JY. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett. 236:1988;205-208.
10. Murtha P, Tindall DJ, Young CY. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry. 32:1993;6459-6464.
11. Grauer LS, Charlesworth C, Saedi MS, Finlay JA, Liu R-S, Kuus-Reichel K, Tindall DJ, Young CY-F. Identification of human glandular kallikrein hK2 from LNCaP cells. J Androl. 17:1996;355-359.
12. Young CY-F, Seay T, Hogen K, Charlesworth MC, Roche PC, Klee GG, Tindall DJ. Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer. Prostate. 1997;. (in press).
13. Bostwick DG. High grade prostatic intraepithelial neoplasia: the most likely precursor of prostate cancer. Cancer. 75:1995;1823-1836.
14. Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate. 29:1996;117-134.
15. Contractor H, Ruschoff J, Ulshofer B, Neumann K, Schultze-Seeman W, Thomas C. Silver-stained structures in prostatic carcinoma: evaluation of diagnostic and prognostic relevance by automated image analysis. Urol Int. 46:1991;9-14.
16. Sakai H, Yogi Y, Minami Y, Yushita Y, Kanetake H, Saito Y. Prostate-specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma. J Urol. 149:1993;1020-1023.
17. Sakai H, Shiraishi K, Minami Y, Yushita Y, Kanetake H, Saito Y. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma. Prostate. 19:1991;265-272.
18. Cohen R, Haffejee Z, Steele GS, Nayler SJ. Advanced prostate cancer with normal serum prostate-specific antigen values. Arch Pathol Lab Med. 118:1994;1123-1126.
19. Gray E, Allison LJ, Edgar S, Robinson E, Cohen RJ. Prostatic adenocarcinoma labeled with a monoclonal antibody and polyclonal serum: a quantitative assessment. Br J Urol. 78:1996;104-108.
20. Wang TJ, Finlay JA, Mikolajczyk S, Rittenhouse HG, Wolfert RL. Analysis of cross-reactivity of anti-PSA monoclonal antibodies with recombinant human glandular kallikrein (abstract). J Urol. 155:1996;695A. (suppl).
21. Diamandis EP. Prostate cancer, prostate-specific antigen, and the polymerase chain reaction. Clin Chem. 41:1995;177-179.